Anixa Biosciences began animal resting of Covid-19 therapeutic candidates
On Feb. 16, 2021, Anixa Biosciences announced that animal testing had commenced with two proprietary compounds that have…
Lonza expanded solid form services for small molecule drugs
On Feb. 16, 2021, Lonza, formerly Bend Research, announced that it was expanding and refining first-in-human services at…
Notch Therapeutics closed $85 million financing to develop pipeline of renewable stem cell-derived cancer immunotherapies
On Feb. 10, 2021, Notch Therapeutics closed $85 Million Series A financing to develop pipeline of renewable stem…
Pfizer and BioNTech data demonstrated COVID-19 vaccine elicited antibodies that neutralize SARS-CoV-2 mutations
On Feb. 8, 2021, Pfizer and BioNTech announced publication in Nature Medicine of data from in vitro studies…
Tonix Pharmaceuticals to develop COVID-19 skin test to measure SARS-CoV-2 exposure and T cell immunity
On Feb. 8, 2021, Tonix Pharmaceuticals announced it had received the written response from the U.S. Food and…
Merck Statement on Ivermectin use During the COVID-19 Pandemic
On Feb. 4, 2021, Merck affirmed its position regarding use of ivermectin during the COVID-19 pandemic, and do…
AXIM Biotechnologies began clinical trials of ImmunoPass rapid diagnostic test with vaccine recipients
On Feb. 3, 2021, AXIM Biotechnologies announced initiation of clinical trials for ImmunoPass, the Companyﾒs rapid point-of-care test…
NeuroRx initiated phase 2/3 study of inhaled ZYESAMI for severe COVID-19 with UCI Health
On Feb. 3, 2021, RELIEF THERAPEUTICS affirmed that its collaboration partner NeuroRx had initiated a phase 2/3 clinical…
Mateon announced completion of ARTI-19 and publication of positive interim data
On Feb. 2, 2021, Mateon Therapeutics announced that its ARTI-19 trial, evaluating ARTIVeda / PulmoHeal against COVID-19 in…
Sorrento announced the fourth patient was released from hospital following third infusion of stem cells
On Jan. 31, 2021, Sorrento Therapeutics announced additional positive results from its Phase 1b study of human allogeneic…
Researchers used patients’ cells to test gene therapy for rare eye disease
On Jan. 28, 2021, scientists at the National Eye Institute (NEI) have developed a promising gene therapy strategy…
CDC study showed 2019-20 flu vaccine effectively prevented hospitalizations and emergency visits in children
On Jan. 27, 2021, a U.S. Centers for Disease Control and Prevention (CDC) study found that the 2019-2020…
In vitro studies demonstrated COVID-19 vaccine elicited antibodies that neutralize SARS-CoV-2 with UK and South African Variants
On Jan. 27, 2021, Pfizer and BioNTech announced results from in vitro neutralization studies of sera from individuals…
Just – Evotec Biologics expanded contract with Department of Defense for manufacturing of monoclonal antibodies
On Jan. 27, 2021, Evotec announced that the U.S. Department of Defense (DOD) awarded its Seattle, Washington-based subsidiary,…
COVID-19 | Diagnostics | Therapeutics | WHO
WHO recommended follow-up care, low-dose anticoagulants for COVID-19 patients
On Jan. 26, 2021, WHO recommends that patients who have COVID-19 – both confirmed and suspected – should…
Sorrento announced positive preliminary results of phase 1b study of COVI-MSC for treatment of ICU COVID-19 patients
On Jan. 26, 2021, Sorrento Therapeutics announced positive preliminary results from its Phase 1b study of human allogeneic…
Regeneron reported positive data with REGEN-COV antibody cocktail as passive vaccine to prevent COVID-19
On Jan. 26, 2021, Regeneron announced positive initial results from an ongoing Phase 3 clinical trial evaluating REGEN-COV…
Medigen’s COVID-19 vaccine announced first participant dosed in phase 2 clinical trial in Taiwan
On Jan. 25, 2021, Medigen Vaccine Biologics and Dynavax Technologies announced that the first participant had been dosed…
Mateon launched mobile app, ARTIHealthTM, remote for respiratory health assessment
On Jan. 25, 2021, Mateon Therapeutics announced that it was launching its mobile app, ARTIHealthTM, for respiratory health…
Biotechnology | Disease | FDA | Therapeutics
FDA approved Aurinia Pharmaceuticals LUPKYNIS (voclosporin) for adults with active lupus nephritis
On Jan. 22, 2021, Aurinia Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) had approved LUPKYNISTM…
Humanigen announced BARDA contract and Expansion of CRADA with U.S. Government for COVID-19
On Jan. 22, 2021, Humanigen announced an expansion to the Cooperative Research and Development Agreement (CRADA) that the…
Cue’s Molecular, point-of-care COVID-19 tests available under HHS and DoD pilot program
On Jan. 19, 2021, Cue Health announced that its molecular, point-of-care COVID-19 Tests were being distributed to five…
Mammoth Biosciences secured U.S. DoD award to develop CRISPR-based diagnostics and biosurveillance platforms
On Jan. 14, 2021, Mammoth Biosciences announced that it had secured a subcontract with MRIGlobal, the prime contractor…
Blood test showed promise for early detection of acute heart transplant rejection
On Jan. 13, 2021, researchers announced they had developed a blood test that could make it possible for…
NIAID scientists studied salmonella swimming behavior as clues to infection
On Jan. 13, 2021, National Institutes of Health scientists and their colleagues announced they had identified a S….
Mateon announced positive interim results from its ARTI-19 clinical trial evaluating ARTIVeda against COVID-19
On Jan. 13, 2021, Mateon Therapeutics reported positive interim results from its ARTI-19 clinical trial evaluating ARTIVedaTM against…
SIGA announced Public Health Agency of Canada contract to purchase $33 million of Oral TPOXX
On Jan. 13, 2021, SIGA Technologies announced that the Public Health Agency of Canada had awarded a contract…
Rising protocol design complexity reported driving rapid growth in clinical trial data volume
On Jan. 12, 2021, the Tufts Center for the Study of Drug Development reported that ever more complex…
Roche’s Xofluza approved by the EC for treatment of influenza, first new influenza antiviral in almost 20 years
On Jan. 11, 2021, Roche announced that the European Commission (EC) had approved Xofluza (baloxavir marboxil) for the…
Biotechnology | CRISPR | FDA | Therapeutics
FDA cleared initiation of the Editas Medicine’s EDIT-301 clinical trial using CRISPR/Cas12a gene editing
On Jan. 11, 2021, Editas Medicine announced the U.S. Food and Drug Administration (FDA) had cleared the initiation…